{"id":1973,"date":"2006-04-01T12:13:00","date_gmt":"2006-04-01T10:13:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2006\/langwirksame-beta-agonisten-bei-asthma-im-kindesalter"},"modified":"2006-04-01T12:13:00","modified_gmt":"2006-04-01T10:13:00","slug":"langwirksame-beta-agonisten-bei-asthma-im-kindesalter","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2006\/langwirksame-beta-agonisten-bei-asthma-im-kindesalter","title":{"rendered":"Langwirksame Beta-Agonisten bei Asthma im Kindesalter"},"content":{"rendered":"<p>In D\u00e4nemark ist die Verordnungsh\u00e4ufigkeit einer fixen Kombination zur Inhalation von Fluticason und Salmeterol bei Kindern im Alter zwischen f\u00fcnf und vierzehn Jahren in den Jahren 2000 bis 2004 um den Faktor f\u00fcnf angestiegen, w\u00e4hrend die Monotherapie mit Fluticason etwa um denselben Faktor zur\u00fcckgegangen ist (1). In einem Editorial im Lancet (2) weisen H. Bisgaard [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In D\u00e4nemark ist die Verordnungsh\u00e4ufigkeit einer fixen Kombination zur Inhalation von Fluticason und Salmeterol bei Kindern im Alter zwischen f\u00fcnf und vierzehn Jahren in den Jahren 2000 bis 2004 um den Faktor f\u00fcnf angestiegen, w\u00e4hrend die Monotherapie mit Fluticason etwa um denselben Faktor zur\u00fcckgegangen ist (1). In einem Editorial im Lancet (2) weisen H. Bisgaard [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[470,467,778,777,3691,2797,3225],"class_list":["post-1973","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-asthma","tag-asthma-bronchiale","tag-beta-agonisten","tag-beta-sympathikomimetika","tag-fluticason","tag-salmeterol","tag-smart-studie"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1973","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1973"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1973\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1973"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1973"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1973"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}